Posts

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501 in Relapsed/Refractory B‑Cell Non‑Hodgkin Lymphoma

on

ArkBio Completes Dosing of First Cohort in Australian Phase I Trial of Antiviral Drug-Fc Conjugate AK0406

on

Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial

on

Makary Proposes Higher FDA User Fees for Non-US Phase I Trials to Counter China Biotech

on

AI-Designed Drug AH-001 Completes U.S. Phase I Trial, Demonstrating Excellent Safety and Tolerability

on

AI-Designed Drug AH-001 Completes U.S. Phase I Trial, Demonstrating Excellent Safety and Tolerability

on